Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 05, 2015 8:27 PM ET


Company Overview of PaxVax, Inc.

Company Overview

PaxVax, Inc. operates as a biotechnology company that develops and commercializes vaccine candidates against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein; a two-dose whole virus inactivated vaccine candidate that encompasses various strains of dengue fever; and Vivotif, a live typh...

900 Veterans Boulevard

Suite 500

Redwood City, CA 94063

United States

Founded in 2006



Key Executives for PaxVax, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 56
Chief Financial Officer and Executive Vice President
Age: 48
Chief Scientific Officer and Executive Vice President
Chief Legal Officer and Executive Vice President
Compensation as of Fiscal Year 2015.

PaxVax, Inc. Key Developments

PaxVax, Inc. Announces Executive Changes

PaxVax, Inc. announced that the Board of Directors has appointed Nima Farzan as Chief Executive Officer and President. In this role, he will assume overall responsibility for PaxVax, including management of all R&D, manufacturing and commercial operations globally. Kenneth Kelley, co-founder and former CEO, will continue to serve PaxVax as a Director on the Company’s Board of Directors and as an Advanced Leadership Initiative Fellow at Harvard University focused on related global health issues. Mr. Farzan previously served as President and Chief Operating Officer. He joined PaxVax in September 2011 from Novartis AG. Most recently, he was Vice President of Marketing for Novartis Vaccines USA, where he was responsible for marketing, market access, pricing and key account sales, and also helped launch multiple new vaccines.

PaxVax, Inc. Announces Global Expansion of Commercial Network for its Typhoid Vaccine Vivotif

PaxVax, Inc. announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif. These agreements will ensure the global availability of Vivotif across Europe and Australia and complement the company's growing direct sales and marketing capabilities in the United States. Vivotif is currently licensed for sale in 27 countries.Typhoid is one of the most commonly delivered travel vaccines, and these agreements will ensure the availability of Vivotif to people in the European and Australian markets who are travelling to regions of the world where typhoid is endemic. Vivotif is the only oral vaccine indicated for typhoid and look forward to working with new distribution partners to maintain a stable global supply of this effective vaccine.

PaxVax, Inc. Appoints Nima Farzan as President

PaxVax, Inc. announced the appointment of Nima Farzan as president and chief operating officer. Mr. Farzan, who has served as PaxVax COO for the past three years, will be responsible for the company’s global operations including the finance, production and commercial functions. The company also announced that Mr. Farzan has joined the company’s board of directors. Kenneth Kelley will continue to serve as the company’s chief executive officer and as a director.

Similar Private Companies By Industry

Company Name Region
Inanovate, Inc. United States
Motif BioSciences, Inc. United States
D. E. Shaw Research, LLC United States
Hypobaric Therapeutics Inc. United States
Quality Controlled Biochemicals, Inc. United States

Recent Private Companies Transactions

July 28, 2014
Crucell Switzerland AG, Vivotif Vaccine & Manufacturing Facility & Certain Travel Vaccines Assets

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PaxVax, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at